IN THIS ISSUE
Legislation & Regulation
Richard Mark Kirkner

James C. Robinson

Designed to pay for breakthroughs, the new technology add-on (NTAP) ‘bump’ is also too unpredictable, say drug and device groups.

Tomorrow's Medicine
Thomas Morrow, MD

Childhood cancer hasn’t been a big money maker. A not-for-profit helped fund the research that led to the approval of a new drug for neuroblastoma.

News & Commentary

"Arterial kateter (Seldinger)" by Privatarchiv Foto von MrArifnajafov

News & Commentary
Frank Diamond